IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 92.34

Change

+0.04 (+0.04)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.09 (+0.06%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.11 (-0.16%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.59 (-0.56%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-0.51 (-0.61%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-0.09 (-0.43%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.10 (-0.32%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.81 (-0.83%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.16 (-0.56%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.26 (-0.42%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.01 (+0.03%)

USD 6.67M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+0.42 (+0.29%)

USD 1.45B
XHC:CA iShares Global Healthcare.. 99.68 % 0.65 %

+0.02 (+0.29%)

CAD 0.57B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.41% 90% A- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.41% 90% A- 82% B
Trailing 12 Months  
Capital Gain 0.39% 57% F 45% F
Dividend Return 1.40% 100% F 27% F
Total Return 1.79% 67% D+ 38% F
Trailing 5 Years  
Capital Gain 72.44% 52% F 51% F
Dividend Return 10.21% 84% B 18% F
Total Return 82.65% 62% D 45% F
Average Annual (5 Year Horizon)  
Capital Gain 5.24% 67% D+ 51% F
Dividend Return 6.20% 71% C- 47% F
Total Return 0.96% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 13.13% 76% C+ 71% C-
Risk Adjusted Return 47.23% 81% B- 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike